T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company, committed to develop and commercialize disease remedial therapeutics for the treatment of Alzheimers disease and other CNS disorders.
T3D Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.t3dtherapeutics.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address68 T.W. Alexander Drive PO Box 13628, NC 27709Research Triangle ParkUnited States
68 T.W. Alexander Drive PO Box 13628, NC 27709
Research Triangle Park
United States
Contact Number+1 919-237-4897
+1 919-237-4897
In June 2013, Dara Biosciences granted T3D Therapeutics, the exclusive worldwide rights to develop and commercialize DB959 / T3D-959. DARA had previously developed DB959 through Phase 1 clinical trials for the treatment of diabetes and dyslipidemia.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/t3d-therapeutics-inc.” connections=”true” suffix=””]
In Mar 2015, T3D Therapeutics awarded SBIR Phase 2 grant from The National Institute on Aging for clinical development of T3D- 959.